Stock·NYSE·Consumer Cyclical
PulteGroup, Inc. (PHM)
- Market cap
- $23.17B
- P/E
- 13.01
- Dividend yield
- 0.86%
- Street target
- $136.00median of 18 analysts
- 52-week range
- $107.16 $144.50
PHM stock forecast today
Where PHM stands today, and what CleaRank Financial AI makes of it.
PHM at a glance
PulteGroup, Inc. (PHM): Hold, 58/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($119.58 and $124.17).
- Earnings PHM beat estimates in 4 of the 6 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $29.3M and made no open-market purchases over the last 18 months.
- Valuation P/E of 13.0 against 20.8 for the Consumer Cyclical sector: a discount to peers (-37%).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates PulteGroup, Inc. (PHM) Hold with a model score of 58/100.
Valuation is the largest contributor to the score. The P/E of 13.01 is 37.4% below the sector median, a discount to peers, and the P/S of 1.45 is 23.7% below the sector median. The trend is mixed, with the price 1.71% above its 50-day average of $119.58 yet 2.05% below its 200-day average of $124.17. Over the past year the price rose 1.11%.
Only on CleaRank
Figures we compute ourselves from PHM's own price, earnings and insider-filing history. Tap one to see it in context.
PHM stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $121.63 is 1.7% above the 50-day simple moving average of $119.58.Price above its 200-day average ›
The price is 2.0% below the 200-day simple moving average of $124.17.50-day average above the 200-day ›
The 50-day average ($119.58) is 3.7% below the 200-day average ($124.17), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 39% of its 52-week range, between $107.16 and $144.50.
PHM share price
Pick a period: each tab shows how far PHM has moved over it, to the last close.
Today's trading
Where PHM sits inside today's range and its 52-week range.
PHM fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 13.01 is 37.4% below the Consumer Cyclical median of 20.8.P/S below the sector median ›
The price-to-sales ratio of 1.45 is 23.6% below the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $1.8B on revenue of $16.0B, a net margin of 11.2%.Beat estimates in most recent reports ›
PHM beat the EPS estimate in 4 of the 6 reports in our data.Pays a dividend ›
The trailing dividend yield is 0.86%, or $1.04 a share a year.
Key statistics
The headline figures for PHM.
As of October 27, 2026, PHM trades at $121.63, with a market value of $23.17B, a P/E ratio of 13.01 and a dividend yield of 0.86%.
What the numbers say
CleaRank Financial AI's reading of PHM's valuation, growth and risks.
PHM's trailing P/E of 13.01 is 37.4% below the Consumer Cyclical median of 20.8, a gap that the peer comparison on this page labels a discount to peers. Measured on sales, the P/S of 1.45 is 23.7% below the sector median of 1.9. With a market value of $23.2B, the company reported trailing earnings of $9.36 per share.
That is 17.0 percentage points slower than the sector median of 7.2%. PHM converts sales into earnings with a net margin of 11.24% and an operating margin of 15.96%. Its return on equity of 13.86% sits above the sector median of 12.4%. Debt-to-equity stands at 0.18, and the trailing dividend yield is 0.86%, equal to $1.04 a share annually.
PHM came up short in its October 22, 2026 report, which missed the estimate by 3.44%: $2.53 a share versus an expected $2.62. The shares still climbed 1.43% in the first session after the release.
PHM has beaten estimates in 4 of the 6 reports in our data, yet the stock fell in the next session after 3 of those 4 beats. Analysts forecast EPS of $9.31 for this fiscal year, a fall of 16.2%, and $9.43 for the year after, a rise of 1.2%.
Daily swings are the main risk to plan around. On an average session PHM moves 2.02%, and its beta against the S&P 500 is 1.16. The stock is 15.83% below its 52-week high of $144.50.
PHM against the Consumer Cyclical sector
How PHM compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: PHM trades at a notable discount to sector peers (-37%), which may indicate undervaluation or specific company headwinds.
Return vs SPY: Since May 15, 2025, PHM has gained 18.4% against a gain of 30.4% for SPY.
Performance against SPY
PHM and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much PHM sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); PHM reported again on October 22, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue fell 3.5% in FY2025 to $17.3B, from $17.9B a year earlier.
Profit margin: The net margin was 12.8% in FY2025, down from 17.2% the year before.
Profitable: PHM earned $2.2B in FY2025.
Earnings reality check
Did PHM beat what analysts expected, and how did the stock react?
Earnings record: PHM beat the analyst estimate in 4 of the 6 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 22, 2026after close | $2.62 | $2.53 | -3.44% | +1.43% | - |
| Apr 23, 2026after close | $1.81 | $1.79 | -1.10% | -2.36% | -6.34% |
| Oct 21, 2025after close | $2.90 | $2.96 | +2.07% | -2.48% | -2.05% |
| Jul 22, 2025after close | $2.97 | $3.03 | +2.02% | -1.56% | -3.39% |
| Apr 22, 2025after close | $2.42 | $2.57 | +6.20% | +0.17% | +0.84% |
| Jan 30, 2025after close | $3.27 | $4.43 | +35.47% | -3.99% | -7.17% |
As of October 27, 2026, PHM has beaten the analyst EPS estimate in 4 of the 6 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on October 22, 2026, came in 3.44% below the estimate and the stock moved +1.43% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
PHM AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 59.4, in neutral territory.RSI above 50 ›
An RSI of 59.4 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of PHM
The score, the reasoning behind it, and what could move the price next.
PHM is caught between its two moving averages. At $121.63, the stock sits 2.05% below its 200-day average of $124.17 but 1.71% above its 50-day average of $119.58. Across the 52-week range, which runs from $107.16 to $144.50, the price is at 39% of the way up.
The short and long run point different ways: the price rose 1.49% over the past month, fell 9.74% over the past three months and rose 1.11% over the past year. The price rose 0.26% in the last session on volume 36.2% above its average. On momentum, the 14-day RSI reads 59.4, in the neutral zone, with the MACD line positive.
Rating reaffirmed ›
UBS kept its Buy rating on October 23, 2026.
Source: Analyst action, UBS, October 23, 2026
Earnings miss, but the stock rose ›
The October 22, 2026 report missed the EPS estimate by 3.44%, and the share price rose 1.43% in the first session after it.
Source: Earnings report, October 22, 2026
- The two nearest levels to watch are the 200-day SMA at $124.17, just above the price, and the 50-day SMA at $119.58, just below it.
- The 14-day RSI stands at 59.4, which is neutral territory, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- PHM beat estimates in 4 of the 6 reports in our data. After the October 22, 2026 report, the share price gained 1.43% in the first session.
PHM has a mixed trend. The price is above its 50-day average of $119.58 but below its 200-day average of $124.17. Closing above the 200-day would turn both signals up, while closing below the 50-day would turn both down. For now the price sits between the 50-day SMA ($119.58) beneath it and the 200-day SMA ($124.17) above it.
Technical indicators
Momentum and trend for PHM, from its daily closes.
As of October 27, 2026, with PHM at $121.63, its 14-day RSI is 59.4 (neutral territory), its 50-day simple moving average is $119.58 and its 200-day is $124.17.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What PHM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, PHM's 1-year correlation of daily returns is +0.36 with S&P 500 (SPY), +0.24 with Nasdaq 100 (QQQ), +0.02 with Bitcoin (BTC) and +0.12 with gold (XAU).
PHM price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
10 of 18 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $136.00 is 11.8% above the price.More buy ratings than three months ago ›
10 of 18 rate it a buy now, against 8 of 15 three months ago.
PHM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 23, 2026 | UBS | Maintains | Buy |
| Oct 23, 2026 | Evercore ISI Group | Maintains | Outperform |
| Oct 23, 2026 | RBC Capital | Maintains | Sector Perform |
| Oct 23, 2026 | Barclays | Maintains | Equal-Weight |
| Oct 15, 2026 | Citigroup | Maintains | Neutral |
| Oct 15, 2026 | RBC Capital | Maintains | Sector Perform |
As of October 27, 2026, 18 Wall Street analysts cover PHM: 10 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $100.00 to $162.00. The median PHM price target is $136.00, 11.8% above the price of $121.63.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
PHM trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
PHM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from PHM's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much PHM tends to move, against the market and on its own.
PHM price history and drawdowns
PHM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 2.02% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 52.5%, from February 2020 to March 2020, regained by August 2020.Most 1-year holds ended higher ›
73% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $74,703, against $42,015 in the S&P 500 (SPY).
PHM Drawdowns & Recovery
As of October 27, 2026, PHM's worst peak-to-trough fall over the last 10 years with dividends reinvested was -52.5% (February 2020 to March 2020); it regained that peak by August 2020, 5 months after the low, and 73% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into PHM in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: PHM beat the S&P 500 over this period: $74,703 against $42,015.
A $10,000 investment in PHM in October 2016 would be worth about $74,703 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to PHM, and which have not.
Strongest month, November: an average of +8.67%, up in 10 of 10 years.
Weakest month, March: an average of -2.35%, up in 6 of 10 years.
This month, October: has averaged -0.88%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, PHM's strongest calendar month has been November (average +8.67%, up in 10 of 10 years) and its weakest March (average -2.35%, up in 6 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
PHM stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in PHM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in PHM today could grow to about $14,848 by 2030 in the base case, with a 90th-percentile outcome near $38,135 and a 10th-percentile outcome around $5,781. The simulation models price only; at today's 0.86% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
PHM Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $181 for PHM by 2030 in the base case, from $122 today (1.5x over 4 years). The 10th-percentile path ends near $70.31. These are outcomes of a Monte Carlo simulation run on PHM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $83.78 | $134 | $215 | |
| 2028 | $76.07 | $148 | $289 | |
| 2029 | $72.28 | $164 | $370 | |
| 2030 | $70.31 | $181 | $464 |
Method: a lognormal simulation of PHM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
PHM insider trading
What the people running the company have bought and sold.
PHM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought PHM shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, PHM insiders reported 10 open-market sales worth $29.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 30, 2026 | Bryce Blair
Director
|
Grant | 7.6K | - |
| May 27, 2026 | Matthew William Koart
Chief Operating Officer
|
Sell | 7.5K | $894.8K |
| May 8, 2026 | Lila Snyder
Director
|
Sell | 3.3K | $391.3K |
| Apr 29, 2026 | Kristen Actis-Grande
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Bryce Blair
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Kristin F Gannon
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Cheryl W Grise
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Andre J Hawaux
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Benjamin Schall
Director
|
Grant | 1.5K | - |
| Apr 29, 2026 | Lila Snyder
Director
|
Grant | 1.5K | - |
| Feb 24, 2026 | Kevin A Henry
Officer
|
Sell | 5.2K | $729.6K |
| Feb 10, 2026 | Kristin F Gannon
Director
|
Grant | 292 | - |
| Feb 6, 2026 | Matthew William Koart
Chief Operating Officer
|
Sell | 15.3K | $2.1M |
| Feb 6, 2026 | Todd N Sheldon
General Counsel
|
Sell | 14.2K | $1.9M |
| Feb 6, 2026 | Brien P. O'Meara
Officer
|
Sell | 4.0K | $542.0K |
| Feb 5, 2026 | Ryan R Marshall
Chief Executive Officer
|
Sell | 111.3K | $14.9M |
| Feb 5, 2026 | Thomas J Folliard
Director
|
Sell | 37.0K | $5.0M |
| Feb 5, 2026 | Ryan R Marshall
Chief Executive Officer
|
Grant | 3.8K | - |
| Feb 4, 2026 | Kevin A Henry
Officer
|
Grant | 12.3K | - |
| Feb 4, 2026 | Matthew William Koart
Chief Operating Officer
|
Grant | 37.0K | - |
| Feb 4, 2026 | Ryan R Marshall
Chief Executive Officer
|
Grant | 150.0K | - |
| Feb 4, 2026 | Brien P. O'Meara
Officer
|
Grant | 5.5K | - |
| Feb 4, 2026 | Shaughnessy Robert T O
Officer
|
Grant | 36.9K | - |
| Feb 4, 2026 | James L Ossowski
Chief Financial Officer
|
Grant | 14.4K | - |
| Feb 4, 2026 | Todd N Sheldon
General Counsel
|
Grant | 20.0K | - |
| Nov 12, 2025 | Todd N Sheldon
General Counsel
|
Grant | 1.0K | - |
| Nov 6, 2025 | Lila Snyder
Director
|
Grant | 1.0K | - |
| Aug 14, 2025 | Shaughnessy Robert T O
Officer
|
Sell | 21.9K | $2.8M |
| Aug 14, 2025 | Brien P. O'Meara
Officer
|
Sell | 814 | $104.2K |
| Aug 14, 2025 | Brien P. O'Meara
Officer
|
Grant | 400 | - |
| Apr 30, 2025 | Kristen Actis-Grande
Director
|
Grant | 1.8K | - |
| Apr 30, 2025 | Brian P Anderson
Director
|
Grant | 1.8K | - |
| Apr 30, 2025 | Bryce Blair
Director
|
Grant | 1.8K | - |
| Apr 30, 2025 | Andre J Hawaux
Director
|
Grant | 1.8K | - |
| Apr 30, 2025 | Lila Snyder
Director
|
Grant | 1.8K | - |
Source: TwelveData, from SEC Form 4 filings
PHM stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.